2025-10-31 06:47:16
Latest Post
SMC Global Securities Ltd Q2 FY2025-26 consolidated net profit declines to Rs. 20.65 crores
Rajoo Engineers Ltd Q2FY26 consolidated profit at Rs. 14.18 crores
Inventurus Knowledge Solutions Ltd consolidated Q2 FY2025-26 PAT climbs to Rs. 180.71 crores
IFB Industries Ltd consolidated PAT for Q2FY26 jumps to Rs. 50.79 crores
Share India Securities Ltd consolidated Q2 FY26 net profit at Rs. 92.91 crores
Stock Report
Jenburkt Pharmaceuticals Ltd Q2 FY2024-25 net profit higher at Rs. 9.60 crores
Posted On : 2024-11-05 17:07:03( TIMEZONE : IST )
JENBURKT PHARMACEUTICALS LTD. has reported Standalone financial results for the period ended September 30, 2024.
Financial Results (Q2 FY2025) - QoQ Comparison
The company has reported total income of Rs. 43.0692 crores during the period ended September 30, 2024 as compared to Rs. 33.9414 crores during the period ended June 30, 2024.
The company has posted net profit / (loss) of Rs. 9.6005 crores for the period ended September 30, 2024 as against net profit / (loss) of Rs. 7.4160 crores for the period ended June 30, 2024.
The company has reported EPS of Rs. 21.75 for the period ended September 30, 2024 as compared to Rs. 16.80 for the period ended June 30, 2024.
| Financials | Q2 FY2025 | Q1 FY2025 | % Change |
| Total Income | ₹ 43.0692 crs | ₹33.9414 crs |  26.89% |
| Net Profit | ₹9.6005 crs | ₹7.4160 crs | 29.46% |
| EPS | ₹21.75 | ₹16.80 | 29.46% |
Financial Results (Q2 FY2025) - YoY Comparison
The company has reported total income of Rs. 43.0692 crores during the period ended September 30, 2024 as compared to Rs.39.3849 crores during the period ended September 30, 2023.
The company has posted net profit / (loss) of Rs.9.6005 crores for the period ended September 30, 2024 as against net profit / (loss) of Rs.7.3218 crores for the period ended September 30, 2023.
The company has reported EPS of Rs.21.75 for the period ended September 30, 2024 as compared to Rs.16.59 for the period ended September 30, 2023.
| Financials | Q2 FY2025 | Q2 FY2024 | % Change |
| Total Income | ₹ 43.0692 crs | ₹39.3849 crs | 9.35% |
| Net Profit | ₹9.6005 crs | ₹7.3218 crs | 31.12% |
| EPS | ₹21.75 | ₹16.59 | 31.10% |
Financial Results (Half Year Ended FY2025) - YoY Comparison
The company has reported total income of Rs.77.0106 crores during the 6 Months period ended September 30, 2024 as compared to Rs.69.5973 crores during the 6 Months period ended September 30, 2023.
The company has posted net profit / (loss) of Rs.17.0165 crores for the 6 Months period ended September 30, 2024 as against net profit / (loss) of Rs.12.6909 crores for the 6 Months period ended September 30, 2023.
The company has reported EPS of Rs.38.56 for the 6 Months period ended September 30, 2024 as compared to Rs.28.76 for the 6 Months period ended September 30, 2023.
| Financials | Half Year Ended FY2025 | Half Year Ended FY2024 | % Change |
| Total Income | ₹77.0106 crs | ₹69.5973 crs | 10.65% |
| Net Profit | ₹17.0165 crs | ₹12.6909 crs | 34.08% |
| EPS | ₹38.56 | ₹28.76 | 34.08% |
Shares of JENBURKT PHARMACEUTICALS LTD. was last trading in BSE at Rs. 1013.00 as compared to the previous close of Rs. 987.15. The total number of shares traded during the day was 1017 in over 82 trades.
The stock hit an intraday high of Rs. 1030.00 and intraday low of 978.00. The net turnover during the day was Rs. 1018461.00.
